Effect of Propofol Supplemented Cardioplegia on Organ Injury Biomarkers in on pump Cardiac Surgery-Randomized controlled study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202510667466311

Enrollment

Registered

2025-10-31

Start date

2025-10-22

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

Propofol group

Delnido group

Classic group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria • Adults aged 18–70 years, both sexes ?• Undergoing first-time elective on-pump cardiac surgery

Exclusion criteria

Exclusion criteria: Redo cardiac surgeries ?• Combined procedures (e.g., CABG + AVR) ?• Known allergy to propofol? • Participation in other concurrent interventional trials

Design outcomes

Primary

Measure	Time frame
Primary outcome is to assess the efficacy of propofol-supplemented cardioplegia in reducing myocardial injury during on-pump cardiac surgery by Serial measurement of cTnT	—

Secondary

Measure	Time frame
- Aortic cross-clamp time (minutes)?- CPB time (minutes)?- Incidence of ventricular fibrillation post-declamping?- Inotrope requirement at OR exit (µg/kg/min, pH, creatinine at serial intervals?- ICU and hospital length of stay?- Incidence of complications (MI, AKI, stroke)	—

Countries

Egypt

Contacts

Public ContactElshima Mahmoud

Lecturer

Alshiamaaagag@gmail.com01067796177

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026